Carl P. Decicco

Flagship Pioneering (United States) — United States

Biochemistry, Genetics and Molecular Biology · Life Sciences

40h-index6.0kcitations154works1.82yr avg
OpenAlex↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Protease and Inhibitor Mechanisms(26), Chemical Synthesis and Analysis(23), Peptidase Inhibition and Analysis(22), Chemokine receptors and signaling(15), Asymmetric Synthesis and Catalysis(12)

Publications154 total

Pharmacologic inhibition of BAF chromatin remodeling complexes as a therapeutic approach to transcription factor-dependent cancers
2025· 1 citedOpen Access
Author response: Pharmacologic inhibition of BAF chromatin remodeling complexes as a therapeutic approach to transcription factor-dependent cancers
2025Open Access
Author response: Pharmacologic inhibition of BAF chromatin remodeling complexes as a therapeutic approach to transcription factor-dependent cancers
2025Open Access
Pharmacologic inhibition of BAF chromatin remodeling complexes as a therapeutic approach to transcription factor-dependent cancers
2025Open Access
Discovery of FHD-286, a First-in-Class, Orally Bioavailable, Allosteric Dual Inhibitor of the Brahma Homologue (BRM) and Brahma-Related Gene 1 (BRG1) ATPase Activity for the Treatment of SWItch/Sucrose Non-Fermentable (SWI/SNF) Dependent Cancers
Journal of Medicinal Chemistry·2025· 16 cited
Reviewer #3 (Public Review): Pharmacologic inhibition of BAF chromatin remodeling complexes as a therapeutic approach to transcription factor-dependent cancers
2024Open Access
Pharmacologic inhibition of BAF chromatin remodeling complexes as a therapeutic approach to transcription factor-dependent cancers
2024Open Access
Pharmacologic inhibition of BAF chromatin remodeling complexes as a therapeutic approach to transcription factor-dependent cancers
2024· 1 citedOpen Access
Reviewer #2 (Public Review): Pharmacologic inhibition of BAF chromatin remodeling complexes as a therapeutic approach to transcription factor-dependent cancers
2024Open Access
Reviewer #1 (Public Review): Pharmacologic inhibition of BAF chromatin remodeling complexes as a therapeutic approach to transcription factor-dependent cancers
2024Open Access
Pharmacologic inhibition of BAF chromatin remodeling complexes as a therapeutic approach to transcription factor-dependent cancers
2023· 7 citedOpen Access
Abstract LB190: Modulation of SPI1 transcriptional program contributes to the preclinical anti-tumor activity of SMARCA4/SMARCA2 ATPase inhibitors in AML
Cancer Research·2022
Abstract 1224: Discovery of novel BAF inhibitors for the treatment of transcription factor-driven cancers
Cancer Research·2021· 3 cited
Structure-Based Design of Macrocyclic Factor XIa Inhibitors: Discovery of the Macrocyclic Amide Linker
Journal of Medicinal Chemistry·2017· 38 citedOpen Access
Catalytic Transformations via C—H Activation 1
2016· 17 cited
Correction to “Synthesis of Biologically Active Piperidine Metabolites of Clopidogrel: Determination of Structure and Analyte Development”
The Journal of Organic Chemistry·2015· 3 citedOpen Access
Synthesis of Biologically Active Piperidine Metabolites of Clopidogrel: Determination of Structure and Analyte Development
The Journal of Organic Chemistry·2015· 29 cited
CCDC 1420747: Experimental Crystal Structure Determination
The Cambridge Structural Database·2015Open Access
CCDC 1420748: Experimental Crystal Structure Determination
The Cambridge Structural Database·2015Open Access
The Changing Face of Innovation in Drug Discovery
2014· 2 cited
page 1 of 8Next →

Frequent Co-authors

Robert Newton(20), Rui‐Qin Liu(19), Maryanne Covington(19), James M. Trzăskos(15), James J.‐W. Duan(12), Zelda R. Wasserman(12), Ronald L. Magolda(10), Elizabeth C. Arner(10), Mingxin Qian(9), Robert J. Cherney(9), Micky D. Tortorella(8), Robert A. Copeland(8), Kimberly A. Solomon(8), Karl D. Hardman(8), David D. Christ(8), Chu‐Biao Xue(7), Ruth R. Wexler(6), Dayton T. Meyer(6), Michael A. Pratta(5), Matthew E. Voss(5)